


PHARMACEUTICAL 2020

TENAX THERAPEUTICS INC. Rank 51 of 362







RealRate

PHARMACEUTICAL 2020

TENAX THERAPEUTICS INC. Rank 51 of 362

The relative strengths and weaknesses of TENAX THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of TENAX THERAPEUTICS INC. compared to the market average is the variable Other Compr. Net Income, increasing the Economic Capital Ratio by 755% points. The greatest weakness of TENAX THERAPEUTICS INC. is the variable Revenues, reducing the Economic Capital Ratio by 323% points.

The company's Economic Capital Ratio, given in the ranking table, is 93%, being 396% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	6,181
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,532
Liabilities, Non-Current	60
Other Assets	178
Other Compr. Net Income	16,789
Other Expenses	0
Other Liabilities	0
Other Net Income	161
Property and Equipment	6.6
Research and Development	3,471
Revenues	0
Selling, General and Administrative Expense	5,084

Output Variable	Value in 1000 USD
Assets	6,365
Liabilities	2,593
Expenses	8,555
Stockholders Equity	3,772
Net Income	-8,394
Comprehensive Net Income	0.029
Economic Capital Ratio	93%

